Showing 2071-2080 of 5789 results for "".
- Sentient’s Tixel Receives FDA Nod for Treatment of Periorbital Wrinkleshttps://practicaldermatology.com/news/sentients-tixel-receives-fda-nod-for-treatment-of-periorbital-wrinkles/2461945/The device combines heat with the forward motion of a medical-grade titanium tip. The U.S. Food and Drug Administration has approved
- Immunotherapy Drug Combo Helps Extend Progression-Free Survival in Metastatic Melanomahttps://practicaldermatology.com/news/immunotherapy-drug-combo-helps-extend-progression-free-survival-in-metastatic-melanoma/2461940/Combining two immune checkpoint inhibitors helps overcome resistance to prior PD-1 therapy in patients with metastatic melanoma, a new study shows. The combination of ipilimumab and nivolumab showed a longer progression-free survival, but also a greater overall response rate t
- US FDA Nod for Generic Protopichttps://practicaldermatology.com/news/us-fda-nod-for-generic-protopic/2461939/The United States Food & Drug Administration (FDA) has approved Tacrolimus Ointment, 0.03%, Glenmark Pharmaceuticals’ generic version of Protopic Ointment, 0.03%. Glenmark's Tacrolimus Ointment, 0.03%, will be distributed in the U.S. by Glenmark Pharma
- First Patient Dosed in Phase 1/2a Trial of AGLE-102 to Treat Severe Second-degree Burnshttps://practicaldermatology.com/news/first-patient-dosed-in-phase-12a-trial-of-agle-102-to-treat-severe-second-degree-burns/2461938/The first patient has been dosed in Aegle Therapeutics Corp.’s Phase 1/2a clinical trial of AGLE-102 for the treatment of severe second-degree burns. AGLE-102 is an investigational product comprised of native extracellular vesicles isolated from allogeneic stem cel
- Leprosy Cases Rise in Florida: What Do Dermatologists Need to Know?https://practicaldermatology.com/news/leprosy-cases-rise-in-florida-what-do-dermatologists-need-to-know/2461935/Leprosy is making headlines because of an outbreak in Florida, and although this disease is still rare, it should be on dermatologists' radar, says Carrie Kovarik, MD, a professor of dermatology and medicine at Perelman School of Medicine at the University of Pennsylvania in Philadelphia
- VitaSea Gives Back: Skincare Brand to Donate 100% of their Proceeds from Online Sales to the Maui Strong Fund through September 2023https://practicaldermatology.com/news/vitasea-gives-back-skincare-brand-to-donate-100-of-their-proceeds-from-online-sales-to-the-maui-strong-fund-through-september-2023/2461931/VitaSea is donating 100% of their proceeds from online sales to the
- NPF Welcomes Four New Board Membershttps://practicaldermatology.com/news/npf-welcomes-four-new-board-members/2461907/The National Psoriasis Foundation (NPF) is adding four new members to the NPF Board of Directors. Andrew Blauvelt, MD, MBA, Valerie Harrison, PhD, Brian Janssen, and Diana Sandler, MD. will serve two-year terms effective July 1, 2023. Dr. Blauvelt will also serve as the Chair
- RoC Skincare Expands The Look Forward Project to Instill Optimism Among the Next Generationhttps://practicaldermatology.com/news/roc-skincare-expands-the-look-forward-project-to-instill-optimism-among-the-next-generation/2461905/RoC Skincare is expanding The RoC Look Forward Project in partnership with Sarah Jessica Parker. The initiative was first launched in 2022 to celebrate the power of optimism and its positive impact on long-term health and wellbeing. Now, the Look Forward
- Golfers Face Higher Risk for Skin Cancerhttps://practicaldermatology.com/news/golfers-face-higher-risk-for-skin-cancer/2461902/New research from the University of South Australia shows that golfers have a higher risk of skin cancer when compared to the general population. Fully 27% of golfers – or one in four – had been diagnosed with skin cancer, as compared with 7% of the gener
- Abeona Therapeutics Submits Briefing Package for Pre-BLA Meeting with FDA in August 2023https://practicaldermatology.com/news/abeona-therapeutics-submits-briefing-package-for-pre-bla-meeting-with-fda-in-august-2023/2461901/Abeona Therapeutics Inc. completed the submission of the briefing package to the U.S. Food and Drug Administration (FDA) for the Company’s pre-Biologics License Application (BLA) meeting in August 2023. The purpose of the meeting is to discuss the format, content, and accept